TSD to aid Eisai's Japanese development of denileukin
This article was originally published in Scrip
Executive Summary
TSD Japan, a private drug development venture, has been granted the exclusive right to co-develop Eisai's cancer product denileukin diftitox for the Japanese market. Eisai has retained the exclusive right to market the fusion protein in what is its home territory.